From clinical translation and regulatory expectations to manufacturing readiness, capital constraints, and commercial viability, experts identify the pressure points shaping the path from discovery to market
To explore the pressures faced by biopharma companies in transitioning therapies from discovery to clinical and commercial readiness.
Approach:
Kevin Schaab, Sr. Drug Development Consultant: Identifies pressure at the preclinical-to-clinical transition, emphasizing the need for safety, tolerability, and early patient trial pathways.
David Claveau, Vice President, Business Development, North America, Sygnature Di…: Highlights the importance of decision quality under time and capital constraints, advocating for integrated discovery to improve data generation.
Jeremy Skillington, CEO, Poolbeg Pharma: Discusses the critical nature of funding and the impact of development stage on financial requirements, noting recent large investments.
Alison Clayton, Strategic Projects Director, Symbiosis Pharmaceutical Services: Addresses the challenge of balancing speed with long-term commercial readiness, particularly for complex biologics.
Cora Griffin, Head of Business Development, Curve Therapeutics Ltd: Points out capital efficiency as a major pressure, especially for emerging biotechs facing funding disparities.
Jane Rhodes, CEO, AstronauTx: Emphasizes the challenge of clinical translation and the need for reliable measures of clinical benefit amid budget constraints.
Key Findings:
The preclinical-to-clinical transition is a critical pressure point requiring demonstration of safety and tolerability.
Emerging companies face high capital risk and must show credible paths to differentiation.
Funding is essential, with companies needing to reach milestones to unlock further investment.
Balancing speed with long-term readiness is crucial in a competitive environment.
Capital efficiency is a significant concern, especially for emerging biotechs in a tight funding landscape.
Clinical translation remains a challenge due to high attrition rates and budget constraints.
Interpretation:
Limitations:
Resource constraints limit the ability of emerging biotechs to manage complex development programs.
High attrition rates in clinical trials hinder the translation of preclinical success.
Conclusion:
The biopharma industry faces multifaceted pressures that require a holistic approach to development and funding.
